Etamiphylline

Etamiphylline
Names


IUPAC name 7-(2-diethylaminoethyl)-1,3-dimethylpurine-2,6-dione
Identifiers
CAS Number	314-35-2^Y
3D model (Jmol)	Interactive image
ChemSpider	26354^N
ECHA InfoCard	100.005.678
KEGG	D07378^Y
PubChem	28329
UNII	221A91BQ2S^Y
InChI InChI=1S/C13H21N5O2/c1-5-17(6-2)7-8-18-9-14-11-10(18)12(19)16(4)13(20)15(11)3/h9H,5-8H2,1-4H3^N Key: AWKLBIOQCIORSB-UHFFFAOYSA-N^N InChI=1/C13H21N5O2/c1-5-17(6-2)7-8-18-9-14-11-10(18)12(19)16(4)13(20)15(11)3/h9H,5-8H2,1-4H3 Key: AWKLBIOQCIORSB-UHFFFAOYAT
SMILES CCN(CC)CCn1cnc2c1c(=O)n(c(=O)n2C)C
Properties
Chemical formula	C₁₃H₂₁N₅O₂
Molar mass	279.33814
Pharmacology
ATC code	R03DA06 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is ^YN ?)
Infobox references

Etamiphylline (or etamiphyllin) is a xanthine intended for use as an anti-asthma agent. It has shown poor to absent effects in human clinical trials.^[1]^[2]

References

↑ Vazquez, C.; Labayru, T.; Rodriguez-Soriano, J. (1984). "Poor bronchodilator effect of oral etamiphylline in asthmatic children". Lancet. 1 (8382): 914. doi:10.1016/s0140-6736(84)91380-1. PMID 6143224.
↑ Addis, G. J. (1984). "Absence of bronchodilatory effect from etamiphylline". Lancet. 1 (8385): 1083. doi:10.1016/s0140-6736(84)91497-1. PMID 6144017.

Drugs for obstructive airway diseases: asthma/COPD (R03)

Adrenergics, inhalants

Short-acting β₂ agonists	Bitolterol Carbuterol Fenoterol Isoetarine Pirbuterol Procaterol Reproterol Rimiterol Salbutamol (albuterol)^#/Levosalbutamol (levalbuterol) Terbutaline Tulobuterol

Long-acting β₂ agonists	Bambuterol Clenbuterol Formoterol/Arformoterol Salmeterol Salmefamol

Ultra-long-acting β₂ agonists	Abediterol Carmoterol Indacaterol Olodaterol Vilanterol

Other	Epinephrine^# Hexoprenaline Isoprenaline (isoproterenol) Orciprenaline (metaproterenol)

Glucocorticoids

Anticholinergics/
muscarinic antagonist

Mast cell stabilizers

Xanthines

Eicosanoid inhibition

Leukotriene antagonists	Montelukast Pranlukast Zafirlukast

Arachidonate 5-lipoxygenase inhibitors	Zileuton

Thromboxane receptor antagonists	Ramatroban Seratrodast

Non-xanthine PDE4 inhibitors	Ibudilast Roflumilast

Others/unknown

Combination products

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the 5/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.